Mind Club

Data as of 11.07.2026 · Primary sources linked · NOT INVESTMENT ADVICE

Disease Pipeline Tools Obesity

Obesity

Programs, trials, and reported weight change for obesity and overweight.

Data as of 11.07.2026

All studies

Ribupatide

Efficacy and Safety of Ribupatide (KAI-9531) Administered Once Weekly in Participants Living With Obesity Who Do Not Have Diabetes

Fujian Shengdi Pharmaceutical Co · Phase 2 · Active, not recruiting · Enrollment 264

NCT07458269

Participants reaching a weight loss threshold

Participants reaching threshold, %

Source: Cited trial source. The denominator is the source figure, when it states one.

No selected arm reports a responder percent.

Show as table
Arm≥5%≥10%≥15%≥20%
Ribupatide: Dose 1n/rn/rn/rn/r
Ribupatide: Dose 2n/rn/rn/rn/r
Ribupatide: Dose 3n/rn/rn/rn/r
Ribupatide: Dose 4n/rn/rn/rn/r
Placebon/rn/rn/rn/r

Not shown

  • Ribupatide: Dose 1: endpoint not reported
  • Ribupatide: Dose 2: endpoint not reported
  • Ribupatide: Dose 3: endpoint not reported
  • Ribupatide: Dose 4: endpoint not reported
  • Placebo: endpoint not reported